Abstract: A computerized system and method for determining an optimum amount of radiopharmaceutical therapy (RPT) to administer, comprising: performing processing associated with obtaining activity image information related to at least one agent for sub-units of at least one imaged organ from at least one detector; performing processing associated with running at least one calculation for the activity image information, using at least one computer application, to obtain absorbed dose rate image information; and performing processing associated with adding the absorbed dose rate image information, using, the at least one computer application, to obtain RPT total absorbed dose image information for the at least one imaged organ; wherein macroscopic distribution measurements that are related to microscopic or sub-unit distribution of the at least one agent are utilized.

Abstract: A computerized system and method are provided for determining an optimum amount of radioactivity to administer to a patient, comprising: assuming an activity retention limit; utilizing the activity retention limit to determine a dose rate for a phantom category; utilizing the dose rate for the phantom category to determine the dose rate for a second phantom category; and utilizing the dose rate for a second phantom category to find information regarding the second phantom category. In other embodiments, a computerized system and method are provided for determining an optimum amount of radioactivity to administer to a patient, comprising: obtaining at least one image relating to anatomy of a particular patient; obtaining multiple images regarding radioactivity distribution over time in the particular patient; combining the radioactivity images with the anatomy images; running a Monte Carlo simulation to obtain dose image information; and using the dose image information to obtain BED and/or EUD information.

Abstract: The disclosure discusses methods for determining absorbed dose information. A tomography imaging device generates an anatomy image relating to anatomy of a particular patient. A tomography imaging device also generates multiple radioactivity images regarding radioactivity distribution of an internally administered pharmaceutical over time in the particular patient. The radioactivity images related to the radioactivity distribution over time are registered. Each radioactivity image is combined with each anatomy image to create activity images. A Monte Carlo simulation for each activity image is run to obtain absorbed dose-rate images of the pharmaceutical at multiple times. The absorbed dose-rate images are integrated over time to obtain a total absorbed dose image. The absorbed dose-rate images and the total absorbed dose image are used to obtain a biologically effective dose (BED) image. The BED image is used to obtain an equivalent uniform does (EUD) of BED values for a chosen anatomical region.

Abstract: In accordance with one or more embodiments, the present invention provides a series of identified radiopharmaceuticals herein termed “imaging surrogates” whose pharmacokinetic behavior matches that of the alphaRPT for several alphaRPTs currently under investigation as cancer therapeutics. Methods for identifying imaging surrogates are also provided. These imaging surrogates can be used to implement a treatment planning approach to radiopharmaceutical therapy of alpha-emitters, enabling treatment to the maximum tolerated organ absorbed dose for individual patients.

Abstract: The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.

Abstract: A method and system of treating a disease for a patient, comprising assigning class data related to a class of patients that have characteristics similar to a specific patient and/or accessing patent data related to the specific patient; and optimizing a treatment plan, the optimizing being determined utilizing properties of a radio-pharmaceutical used to treat the patient and the class data and/or the patient data.

Abstract: A system and method for adjusting count rate information, comprising: acquiring, using at least one detector, static image information from at least one imaged object; acquiring, using the at least one detector, whole body image information from the at least one imaged object; determining, using at least one computer application, the count rate information using the static image information and the whole body image information; and adjusting, using the at least one computer application, the count rate information by accounting for movement between the at least one detector and the at least one imaged object.

Abstract: A computerized method and system for determining an optimum amount of Internal Radionuclide Therapy (IRT) and External Radiation Therapy (XRT) to administer, comprising: obtaining activity image information for an imaged object from a detector; running a Monte Carlo simulation for the activity image information to obtain absorbed dose-rate image information at multiple times; adding the absorbed dose-rate image information from each time to obtain IRT total absorbed dose image information; and utilizing the IRT total dose image information to obtain total dose image information that is equivalent to XRT dose image information in terms of dose-rate, wherein the IRT dose information is converted to equivalent XRT dose information without having to generate BED dose maps.

Abstract: The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

Abstract: A computerized system and method for determining an optimum amount of radiopharmaceutical therapy (RPT) to administer, comprising: performing processing associated with obtaining activity image information related to at least one agent for sub-units of at least one imaged organ from at least one detector; performing processing associated with running at least one calculation for the activity image information, using at least one computer application, to obtain absorbed dose rate image information; and performing processing associated with adding the absorbed dose rate image information, using, the at least one computer application, to obtain RPT total absorbed dose image information for the at least one imaged organ; wherein macroscopic distribution measurements that are related to microscopic or sub-unit distribution of the at least one agent are utilized.

Abstract: A system and method for adjusting count rate information, comprising: acquiring, using at least one detector, static image information from at least one imaged object; acquiring, using the at least one detector, whole body image information from the at least one imaged object; determining, using at least one computer application, the count rate information using the static image information and the whole body image information; and adjusting, using the at least one computer application, the count rate information by accounting for movement between the at least one detector and the at least one imaged object.

Abstract: The present invention relates to methods for preventing, reducing or treating a variety of conditions, including cancer, and vaccines, compositions and liposomes used to elicit or amplify an immune response specific to the condition by delivering to the spleen of an individual a pegylated liposome construct having a diameter of greater than about 300 nm and including a therapeutic agent and an adjuvant for eliciting or amplifying the immune response.

Abstract: A computerized method and system for determining an optimum amount of Internal Radionuclide Therapy (IRT) and External Radiation Therapy (XRT) to administer, comprising: obtaining activity image information for an imaged object from a detector; running a Monte Carlo simulation for the activity image information to obtain absorbed dose-rate image information at multiple times; adding the absorbed dose-rate image information from each time to obtain IRT total absorbed dose image information; and utilizing the IRT total dose image information to obtain total dose image information that is equivalent to XRT dose image information in terms of dose-rate, wherein the IRT dose information is converted to equivalent XRT dose information without having to generate BED dose maps.

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha emitting constructs have high specific activity.

Abstract: In one embodiment, a computerized system and method are provided for determining an optimum amount of radioactivity to administer to a patient, comprising: assuming an activity retention limit; utilizing the activity retention limit to determine a dose rate for a phantom category; utilizing the dose rate for the phantom category to determine the dose rate for a second phantom category; and utilizing the dose rate for a second phantom category to find information regarding the second phantom category.

Abstract: The present invention relates to a method for the treatment of cancer in a patient in need thereof. The method comprises administering to a patient in need thereof a first amount of a histone deacetylase inhibitor in a first treatment procedure, and a second amount or dose of radiation in a second treatment procedure. The first and second treatments together comprise a therapeutically effective amount. The combination of the HDAC inhibitor and radiation therapy is therapeutically synergistic.

Abstract: The present invention provides targeted delivery of alpha particle-emitting radionuclides and their alpha-emitting progeny using liposomal encapsulation to reduce the loss of daughter radionuclides from the targeting vehicle and, therefore, from the tumor site. Also provided are encapsulated alpha particle-emitting radionuclides.

Abstract: The present invention provides a method to target delivery of antibody constructs radiolabeled with an alpha-particle emitting radionuclide to intravascularly disseminated tumor cells while minimizing systemic toxicity. Targeted delivery of a construct specific for a protein expressed on the tumor cells in combination with rapid clearance of intravascular non-targeted radiolabeled antibody construct minimizes alpha particle emissions from the radionuclide and its alpha-particle emitting decay intermediates to non-targeted cells.